leadf
logo-loader
viewAlgernon Pharmaceuticals Inc.

Algernon announces 25% enrollment for its Phase 2 idiopathic pulmonary fibrosis and chronic cough study of Ifenprodil

The purpose of the open-label, proof-of-concept Phase 2 human trial of 20 patients is to determine the efficacy of Ifenprodil to preserve lung function

lung
There are five sites in total participating in the study with three located in Australia and two in New Zealand

Algernon Pharmaceuticals Inc (CSE:AGN) (OTCB:BTHCF) (FRA:AGW) announced that it has reached 25% of its enrollment target for its Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough clinical study of its re-purposed drug NP-120 (Ifenprodil).

“I am very pleased to report that we have reached 25% enrollment in the study,” said CEO Christopher J. Moreau in a statement.

“While our COVID-19 clinical trial program has received a great deal of attention, IPF and chronic cough are very serious conditions as well, and our team is working hard to make sure our clinical program of investigating Ifenprodil as a possible treatment continues to move forward on schedule.”

READ: Algernon Pharmaceuticals names Dr Mark Swaim to its medical and scientific advisory board

Vancouver-based Algernon said the purpose of the open-label, proof-of-concept Phase 2 human trial of 20 patients is to determine the efficacy of Ifenprodil in the preservation of lung function in IPF patients (including biomarkers of fibrosis) and its associated cough. 

There are five sites in total participating in the study with three located in Australia and two in New Zealand.

Ifenprodil has been shown to mediate anti-inflammatory responses and reduce pulmonary fibrosis in a murine model of (IPF). In addition, Ifenprodil significantly reduced both cough frequency and onset in a guinea pig acute cough model.

The drug is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB). Ifenprodil prevents glutamate signaling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

 

 

Quick facts: Algernon Pharmaceuticals Inc.

Price: 0.305 CAD

CSE:AGN
Market: CSE
Market Cap: $33.57 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Algernon Pharmaceuticals Inc. named herein, including the promotion by the Company of Algernon Pharmaceuticals Inc. in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Algernon Pharmaceuticals enrolls final patient in Phase 2b/3 human study of...

Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive to bring news the company has enrolled their final patient multinational Phase 2b/3 human study of Ifenprodil for the treatment of COVID-19. Moreau telling Proactive the aggregate...

4 hours, 28 minutes ago

2 min read